Faruqi & Faruqi Alerts Investors of AQST Class Action Deadline Approaching Soon

In a significant development for investors holding shares in Aquestive Therapeutics, Inc. (NASDAQ: AQST), leading national securities law firm Faruqi & Faruqi, LLP, has issued a reminder regarding the upcoming deadline for a securities class action. Investors who acquired shares between June 16, 2025, and January 8, 2026, have until May 4, 2026, to apply to be the lead plaintiff in this important legal action.

The Allegations Against Aquestive Therapeutics

The core of the legal case revolves around allegations that Aquestive and its executives engaged in misrepresentation and failed to adequately disclose critical information about their New Drug Application (NDA) for Anaphylm. The lawsuit claims that the company downplayed or concealed key human factors related to the use and administration of its sublingual film product. Specifically, these shortcomings highlight deficiencies in packaging, use instructions, administration guidelines, and labeling, all integral aspects that can affect the product's viability in the market.

The company’s plight began to unravel publicly on January 9, 2026, when the President and CEO disclosed that the FDA had identified deficiencies within the NDA. This notification not only halted discussions about labeling and post-marketing commitments but also triggered a sharp decline in the company’s stock price. Following this announcement, the stock plummeted by $2.30 per share, representing a staggering drop of 37.04%, which closed the market at $3.91 per share.

Implications for Investors

Investors who suffered losses due to these developments are strongly encouraged to reach out to Faruqi & Faruqi, LLP for legal consultation. They maintain that the most financially invested individual from the class, who represents the typical characteristics of the class members, will serve as the lead plaintiff in the case. Those wishing to participate can either nominate themselves as lead plaintiff through their chosen legal counsel or opt to remain an absent member of the class without jeopardizing their potential recovery.

Faruqi & Faruqi also aims to gather more information regarding the actions of Aquestive from various stakeholders, including former employees and shareholders who may not yet be aware of their legal standing.

How to Get Involved

For those who believe they have a claim related to the issues surrounding Aquestive Therapeutics, the firm has provided multiple channels for investors to gain further insights. Interested parties can visit the firm’s dedicated webpage on this matter or directly contact Senior Partner, James (Josh) Wilson, via phone. To learn more, visit www.faruqilaw.com/AQST or call 877-247-4292. The firm stresses that all communications will remain confidential and invites any potential whistleblowers or those with relevant information to come forward.

As the deadline approaches, it remains crucial for investors of Aquestive Therapeutics to stay informed. Keeping track of developments in this case could lead to significant legal and financial implications. Faruqi & Faruqi's commitment to recovering investor losses positions them as a key player in this ongoing situation.

With this class action, affected investors have the opportunity to collectively address grievances and seek the accountability they deserve from Aquestive Therapeutics. Stay updated on the case by following the firm on platforms such as LinkedIn, X, or Facebook.